Torii Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Torii Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Torii Pharmaceutical Co Ltd Strategy Report
- Understand Torii Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Torii Pharmaceutical Co Ltd (Torii Pharma), a subsidiary of Japan Tobacco Inc, manufactures and markets pharmaceuticals for the treatment of renal diseases, skin diseases and allergies. The company’s marketed portfolio spans topical corticosteroids, therapeutic agents for hyperphosphatemia, oral therapeutic agents for pruritus and therapeutic agents for hyperkalemia. It also offers Japanese cedar pollen sublingual drops, Japanese cedar pollen sublingual tablets, and house dust mite sublingual tablets for the treatment of various allergies. Torii Pharma markets its products through its network of distributors. The company operates through its offices in Sendai, Saitama, Tokyo, Nagoya, Osaka, Hiroshima, and Fukuoka. Torii Pharma is headquartered in Chuo, Tokyo, Japan.
Headquarters
Japan
Address
Torii Nihombashi Bldg., 3-4-1, Nihombashi Hon-Cho, Chuo-Ku, Tokyo, 103-8439
Website
www.torii.co.jp
Telephone
81 3 32316811
No of Employees
583
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4551 (TYO)
Revenue (2022)
$403.6M
11.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
4.5%
(2022 vs 2021)
Market Cap*
$702.7M
Net Profit Margin (2022)
XYZ
-6.6%
(2022 vs 2021)
* As of and is in US$
Torii Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Riona Tablets- Hyperphosphatemia | Antebate |
| Remitich- Pruritus | Corectim |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2020 | Contracts/Agreements | In August, the company has entered into agreement with Verrica Pharmaceuticals Inc to develop and commercialize Verrica's VP-102, a skin disease drug in Japan. |
| 2020 | New Products/Services | In June, the company launched Corectim (delgocitnib), a topical janus kinase (JAK) inhibitor for atopic dermatitis. |
| 2020 | Contracts/Agreements | In June, the company has entered into co-promotion agreement with ASKA Pharmaceutical Co Ltd for new indication for Riona. |
Competitor Comparison
| Key Parameters | Torii Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Sumitomo Pharma Co Ltd | Maruho Co Ltd | Daito Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Osaka-Shi | Kita | Toyama-Shi |
| State/Province | Tokyo | Tokyo | Osaka | Osaka | Toyama |
| No. of Employees | 583 | 7,604 | 6,250 | 1,547 | 1,011 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Goichi Matsuda | Chief Executive Officer; Director; President | Executive Board | 2019 | - |
| Masaki Sunami | Executive Officer | Senior Management | - | - |
| Noriaki Nishino | Executive Officer | Senior Management | - | - |
| Nobumasa Kondo | Senior Executive Officer | Senior Management | - | - |
| Atsuyuki Kakee | Senior Executive Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer